✦ LIBER ✦

Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?

✍ Scribed by Alessio Aghemo; Maria Grazia Rumi; Massimo Colombo

Book ID: 108886130
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 25 KB
Volume: 15
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2008.00975.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.252 Short term treatment with peginter

P.252 Short term treatment with peginterferon and ribavirin for HCV genotype 2 or 3 patients

✍ M.L. Gill; M. Atiq; S. Sattar; M.S. Beg; T.A. Shah 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 259 KB

[606] COMPARISON OF PEGINTERFERON a-2a A

[606] COMPARISON OF PEGINTERFERON a-2a AND RIBAVIRIN FOR 12 OR 24 WEEKS IN PATIENTS WITH HCV GENOTYPE 2/3: THE NORDYNAMIC TRIAL

✍ M. Lagging; C. Pedersen; M. Rauning Buhl; M. Farkkila; N. Langeland; K. Morch; G 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 144 KB

236 TWELVE-WEEK COURSE OF PIFN-α-2A/RIBA

236 TWELVE-WEEK COURSE OF PIFN-α-2A/RIBAVIRIN IS AN OPTIMIZED REGIMEN FOR TREATMENT OF HCV GENOTYPE 2 BUT NOT GENOTYPE 3 NON-CIRRHOTIC PATIENTS WITH RVR

✍ L.E. Adinolfi; R. Zampino; B. Guerrera; L. Restivo; L. Rinaldi; A. Ciervo; V.R. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Predicting treatment outcome following 2

Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6

✍ Esther Lukasiewicz; Kristoffer Hellstrand; Johan Westin; Carlo Ferrari; Avidan U 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

We sought to validate FIB-4 using data retrospectively collected from treatment-naive HIV/HCV patients. The original model was adapted in order to use AST and ALT levels expressed as times the upper limit of normality (ϫULN), as follows: (age [yr] ϫ AST [ϫULN]) ϫ 10/((PLT [10 9 /l]) ϫ (ALT [ϫULN]) 1

642 INDIVIDUALIZED TREATMENT DURATION WI

642 INDIVIDUALIZED TREATMENT DURATION WITH PEGINTERFERON-ALFA-2B AND RIBAVIRIN FOR 24, 30 OR 36 WEEKS IN HCV GENOTYPE1-INFECTED PATIENTS WITH UNDETECTABLE HCV-RNA EARLY DURING THERAPY (INDIV-2 STUDY)

✍ C. Sarrazin; S. Schwendy; B. Möller; N. Dikopoulos; P. Buggisch; J. Encke; G. Te 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

[128] PEGINTERFERON o-2b AND RIBAVIRIN F

[128] PEGINTERFERON o-2b AND RIBAVIRIN FOR 14 OR 24 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 AND RAPID VIROLOGICAL RESPONSE. THE NORTH-C TRIAL

✍ O. Dalgard; K. Bjoro; H. Ring-Larsen; H. Verbaan 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 82 KB